

DAFTAR PUSTAKA

1. Aditya, R. *et al.* (2020) 'Validity and reliability of melasma quality of life scale questionnaire in Bahasa Indonesia for female patients', *Journal of General - Procedural Dermatology & Venereology Indonesia*, 4(2), pp. 58–65. doi: 10.19100/jdvi.v4i2.170.
2. Anju George (2016) 'Tranexamic acid: An emerging depigmenting agent', *Pigment International*, 3, pp. 66–71. doi: 10.4103/2349-5847.196295.
3. Anwar, A. I. *et al.* (2019) 'Randomized control trial outcomes of tranexamic acid combination serum as a depigmenting agent for the use in healthy individuals', *Dermatologic Therapy*, 32(6), pp. 1–5. doi: 10.1111/dth.13146.
4. Arbab, A. and Eltahir, M. M. (2010) 'Review on skin whitening agents', *Khartoum Pharm J*, 13(1), pp. 5–9.
5. Asditya, A. and Sukanto, H. (2017) 'Studi Retrospektif: Profil Pasien Melasma', *Berkal Ilmu Kesehatan Kulit dan Kelamin*, 29(3), pp. 221–30.
6. Ashfaq, M. *et al.* (2014) 'Derivatization / chromophore introduction of tranexamic acid and its HPLC determination in pharmaceutical formulations', *Journal of the Association of Arab Universities for Basic and Applied Sciences*, (October), pp. 1–7. doi: 10.1016/j.jaubas.2014.02.005.
7. Atefi, N. *et al.* (2017) 'Therapeutic Effects of Topical Tranexamic Acid in Comparison with Hydroquinone in Treatment of Women with Melasma', *Dermatology and Therapy*, 7(3), pp. 417–424. doi: 10.1007/s13555-017-0195-0.
8. Baumann, L. S. and Cosmetic, B. (2008) 'Understanding and treating various skin types: The Baumann Skin Type Indicator', *Dermatologic Clinics*, 26(8), pp. 359–73. doi: 10.1016/j.det.2008.03.007.
9. Bhattarai, S. *et al.* (2021) 'Clinical patterns and epidemiological characteristics of melasma in a tertiary care hospital of Nepal', *Pigment International*, 4, pp. 35–38. doi: 10.4103/2349-5847.208296.
10. Del Bino, S., Duval, C. and Bernerd, F. (2018) 'Clinical and biological characterization of skin pigmentation diversity and its consequences on UV impact', *International Journal of Molecular Sciences*, 19(9). doi: 10.3390/ijms19092668.
11. Bino, S Del *et al.* (2013) 'Variations in skin colour and the biological consequences of ultraviolet radiation exposure', *British Journal of Dermatology*, 169(Suppl 3), pp. 33–40. doi: 10.1111/bjd.12529.
12. Charlton, M. *et al.* (2020) 'The effect of constitutive pigmentation on the measured emissivity of human skin', *PLoS ONE*, 15(11), pp. 1–9. doi: 10.1371/journal.pone.0241843.
13. Cho, Y. H. *et al.* (2017) 'Tranexamic acid inhibits melanogenesis by activating the autophagy system in cultured melanoma cells', *Journal of Dermatological Science*, pp. 1–22. doi: 10.1016/j.jdermsci.2017.05.019.



14. Clarys, P. *et al.* (2000) 'Skin color measurements: comparison between three instruments: the Chromameter A, the DermaSpectrometer A and the Mexameter A', *Skin Research and Technology*, 6(17), pp. 230–238.
15. Couteau, C. and Coiffard, L. (2016) 'Overview of skin whitening agents: Drugs and cosmetic products', *Cosmetics*, 3(3), pp. 1–16. doi: 10.3390/cosmetics3030027.
16. Dashore, S. and Mishra, K. (2017) 'Tranexamic Acid in Melasma: Why and How?', *Indian Journal of Drugs in Dermatology*, 3(2), pp. 61–3.
17. Deng, L. and Xu, S. (2018) 'Adaptation of human skin color in various populations', *Hereditas*, 155(1), pp. 1–12. doi: 10.1186/s41065-017-0036-2.
18. Ebanks, J. P., Wickett, R. R. and Boissy, R. E. (2009) 'Mechanisms regulating skin pigmentation: The rise and fall of complexion coloration', *International Journal of Molecular Sciences*, 10(9), pp. 4066–4087. doi: 10.3390/ijms10094066.
19. Ebrahim, H. *et al.* (2020) 'Tranexamic Acid for Melasma Treatment: A Split-', *Dermatologic Surgery*, (September), pp. 1–6. doi: 10.1097/DSS.0000000000002449.
20. Ferreira, I., Magina, S. and Moura, D. (2013) 'Mechanisms regulating melanogenesis', *Anais Brasileiros de Dermatologia*, 88(1), pp. 76–83.
21. Gadre, A. and Stoller, J. K. (2017) 'Tranexamic Acid for Hemoptysis: A review', *Clinical Pulmonary Medicine*, 24(2), pp. 69–74. doi: 10.1097/CPM.0000000000000200.
22. Hameed Gatea, A. (2020) 'Review on analysis of interesting whitening agents in cosmetics products', *IOP Conference Series: Materials Science and Engineering*, 928(5), pp. 1–9. doi:10.1088/1757-899X/928/5/052001.
23. Handel, A. C., Miot, L. D. B. and Miot, H. A. (2014) 'Melasma: A clinical and epidemiological review', *Anais Brasileiros de Dermatologia*, 89(5), pp. 771–782. doi: 10.1590/abd1806-4841.20143063.
24. He, S. Y. *et al.* (2014) 'Self-Reported Pigmentary Phenotypes and Race are Significant but Incomplete Predictors of Fitzpatrick Skin Phototype in an Ethnically Diverse Population', *J Am Acad Dermatol*, 71(4), pp. 731–737. doi: 10.1016/j.jaad.2014.05.023. Self-Reported.
25. Irfanti, R. T. *et al.* (2021) 'Terapi Topikal Kombinasi Krim Asam Traneksamat 3 %, Nikotinamid 3 %, dan Microneedling pada Pasien Melasma (Pilot Study)', *Cermin Dunia Kedokteran*, 48(3), pp. 154–160.
26. Ishii, H. *et al.* (2012) 'Evaluation of the Skin Blanching of Topically Applied Steroids Using a Chroma Meter in Animals', *Exp Anim*, 61(September 2011), pp. 147–156.
- Jablonski, N. G. and Chaplin, G. (2010) 'Human skin pigmentation as an adaptation to UV radiation', *PNAS*, 107(Suppl. 2), pp. 8962–8. doi: 10.1073/pnas.0914628107.
27. Kaur, A., Bhalla, M. and Sarkar, R. (2020) 'Tranexamic acid in melasma: a review', *Pigment International*, 7, pp. 12–25. doi: 10.4103/Pigmentinternational.Pigmentinternational.

28. Kimball, A. B. (2008) 'Skin Differences, Needs, and Disorders across Global Populations', *Journal of Investigative Dermatology Symposium Proceedings*, 13(1), pp. 2–5. doi: 10.1038/jidsymp.2008.5.
29. Ly, B. C. K. *et al.* (2020) 'Research Techniques Made Simple: Cutaneous Colorimetry: A Reliable Technique for Objective Skin Color Measurement', *Journal of Investigative Dermatology*, 140(1), pp. 3–12.e1. doi: 10.1016/j.jid.2019.11.003.
30. Mello, S. A. N. D. *et al.* (2016) 'Signaling Pathways in Melanogenesis', *Int J Mol Sci*, 17, pp. 1–18. doi: 10.3390/ijms17071144.
31. Murlistyarini, S. and Hidayah, N. (2019) 'Melasma Tipe Epidermal Diterapi Dengan Injeksi Asam Traneksamat Intradermal Serial Dan Tabir Surya', *Majalah Kesehatan*, 6(1), pp. 67–75. doi: 10.21776/ub.majalahkesehatan.006.01.7.
32. Ng, W., Jerath, A. and Wasowicz, M. (2015) 'Tranexamic acid: A clinical review', *Anaesthesiology Intensive Therapy*, 47(4), pp. 339–350. doi: 10.5603/AIT.a2015.0011.
33. Pazyar, N. *et al.* (2019) 'Comparison of the efficacy of intradermal injected tranexamic acid vs hydroquinone cream in the treatment of melasma', *Clinical, Cosmetic and Investigational Dermatology*, 12, pp. 115–122. doi: 10.2147/CCID.S191964.
34. Prima Minerva (2012) *Hiperpigmentasi Kulit*. Available at: <https://osf.io/9awq6/download>. Qazi, I., Dogra, N. K. and Dogra, D. (2017) 'Melasma: A Clinical and Epidemiological Study', *International Journal of Contemporary Medical Research*, 4(10), pp. 2087–2089. Sabancilar, E. *et al.* (2011) 'Treatment of melasma with a depigmentation cream determined with colorimetry', *Journal of Cosmetic and Laser Therapy*, (February), pp. 255–259. doi: 10.3109/14764172.2011.606463.
35. Sachdeva, S. (2009) 'Fitzpatrick skin typing: Applications in dermatology', *Indian J Dermatol Venereol Leprol*, 75(1), pp. 93–96.
36. Saleh, F. Y. *et al.* (2019) 'Topical tranexamic acid with microneedling versus microneedling alone in treatment of melasma: Clinical, histopathologic, and immunohistochemical study', *Journal of the Egyptian Women's Dermatologic Society*, 16(2), pp. 89–96. doi:10.4103/JEWD.JEWD_25_19.
37. Sarkar, R. *et al.* (2019) 'Clinical and epidemiologic features of melasma: A multicentric cross-sectional study from India', *International Journal of Dermatology*, pp. 1–6. doi: 10.1111/ijd.14541.
38. Soundarya, S. and Srinivasan, M. S. (2020) 'Tranexamic acid in dermatology', *Annals of Tropical Medicine and Public Health*, 23(15). doi: 10.36295/ASRO.2020.231509.
39. Soyata, A. and Chaerunisaa, A. Y. (2021) 'Whitening Agent: Mekanisme, Sumber Dari Alam dan Teknologi Formulasinya', *Majalah Farmasetika*, 6(2), pp. 169–186.
40. Suryaningsih, B. E. (2020) 'Melanogenesis and its associated signalings', *Bali Medical Journal*, 9(1), pp. 327–331. doi: 10.15562/bmj.v9i1.1796.


41. Tzouveka, E. (2015) 'Epidemiology and Risk Factors of Melasma', *Journal of Pigmentary Disorders*, s4, pp. 10–12. doi: 10.4172/2376-0427.1000s1002.

42. Vashi, N. A. and Kundu, R. V (2013) 'Facial hyperpigmentation : causes and treatment', *British Journal of Dermatology*, 169(Suppl. 3), pp. 41–56. doi: 10.1111/bjd.12536.

LAMPIRAN



ALat Chromameter



Pemeriksaan Lampu Wood





KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari.,MMed,PhD., SpGK TELP. 081241850858. 0411 5780103. Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 394/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 8 Agustus 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22060262		No Sponsor	
Peneliti Utama	dr. Nurul Indah Pratiwi		Sponsor	
Judul Peneliti	Perbandingan efektivitas asam traneksamat dengan teknik injeksi intradermal dan microneedling pada pasien melasma			
No Versi Protokol	2	Tanggal Versi	30 Juli 2022	
No Versi PSP	2	Tanggal Versi	30 Juli 2022	
Tempat Penelitian	RS Universitas Hasanuddin dan RSUP Dr. Wahidin Sudirohusodo Makassar			
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 13 Juli 2022		Masa Berlaku	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)		Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

